FY17 Q2 Business Update + Appendix 4C
Respiratory technology company Rhinomed Limited (ASX: RNO) is pleased to report a record unaudited half yearly result of $1.195 million. This follows another strong quarter of operational revenue of $662k.
Respiratory technology company Rhinomed Limited (ASX: RNO) is pleased to report a record unaudited half yearly result of $1.195 million. This follows another strong quarter of operational revenue of $662k.